Dual Publications in the New England Journal of Medicine Highlight Transformative Potential of Imetelstat in Hematologic Myeloid Malignancies
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/13/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
Oppenheimer Remains Bullish on Geron Corp (GERN) Following Two Articles in NEJM
September 3, 2015 11:06 AM EDTOppenheimer reiterated an Outperform rating and $5.50 price target on Geron Corporation (NASDAQ: GERN) following the publication of two articles in the New England Journal of Medicine (NEJM). The article highlight the company's flagship compound imetelstat for the treatment of essential thrombocythemia (ET) and myelofibrosis (MF).... More
Geron Corp (GERN) Announces Publication of Two Papers in NEJM Highlighting Imetelstat
September 2, 2015 5:04 PM EDTGeron Corp (Nasdaq: GERN) announced the publication of two papers in The New England Journal of Medicine (NEJM) in which the companys telomerase inhibitor, imetelstat, was shown to have disease-modifying activity thought to be associated with selective inhibition of the malignant progenitor cell clones responsible for the underlying disease in two hematologic myeloid malignancies, essential thrombocythemia (ET) and myelofibrosis (MF). The papers are available online in the September 3rd issue at www.NEJM.org.
The data in the ET and MF study publications in The New England Journal of Medicine provide compelling... More
